๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial

โœ Scribed by Paul J. Reading; Anna K Luce; Ian G. McKeith

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
1018 KB
Volume
16
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis

Abstract

This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug. ยฉ 2001 Movement Disorder Society.

๐Ÿ“œ SIMILAR VOLUMES

Rivastigmine in the treatment of dementi
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial
โœ Ian G. McKeith; Janet B. Grace; Zuzana Walker; E. Jane Byrne; David Wilkinson; T ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 81 KB ๐Ÿ‘ 2 views

The objective of this study was to assess the tolerability and efficacy of rivastigmine in a group of patients with probable dementia with Lewy bodies (DLB), using an open label study. Open label treatment was with rivastigmine up to maximum tolerated dose (mean 9.6 mg daily, range 3-12 mg). Eleven

Risperidone in the treatment of dopamine
Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
โœ Erich Mohr; Tilak Mendis; Kathleen Hildebrand; Peter Paul De Deyn ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB ๐Ÿ‘ 2 views

## Purpose: To evaluate the safety and efficacy of risperidone in patients with parkinson's disease (pd) who are experiencing significant dopamine-induced psychosis. ## Patients and methods: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3